BrainStorm Cell Therapeutics Announces Peer Reviewed Publication of Results from the NurOwn(R) Phase 2 Progressive MS Trial in Multiple Sclerosis Journal
Data demonstrate NurOwn's safety and provide preliminary evidence of efficacy in patients with progressive multiple sclerosis
Biomarker analyses show consistent treatment effects in neuroinflammation and neuroprotection pathways
NEW YORK, Sept. 15, 2... Regenerative Medicine, Neurology BrainStorm Cell Therapeutics, NurOwn, multiple sclerosis, stem cell
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Brain | Multiple Sclerosis | Neurology | Pharmaceuticals | Stem Cell Therapy | Stem Cells